The sell-off of this pharmaceutical giant might be overdone. Once a market darling during the early pandemic years, Pfizer ( ...

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Pfizer Inc. and Genmab are conducting a Phase 4 ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Pfizer Inc. today announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in ...

Demand for Pfizer’s COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.

Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.

Pfizer Oncology will be joined at the campus by leading global medical technology company BD (Becton, Dickinson and Co.), which began a phased move-in of its San Diego workforce in late 2023.